ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1591879
This article is part of the Research TopicCommunity Series in Immunological Precision Therapeutics: Integrating Multi-Omics Technologies and Comprehensive Approaches for Personalized Immune Intervention: Volume IIView all 18 articles
Study of the interaction between cardiometabolic index and inflammatory index on the risk of prostate cancer development
Provisionally accepted- 1School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang Uyghur Region, China
- 2Department of Maternal and Child Health, School of Public Health, Health Science Centre, Peking University, Beijing, Beijing Municipality, China
- 3Department of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
AbstractBackground: Prostate cancer (PCa) is an important cause of fatality in older men, with inflammation and metabolic disorders as risk factors for PCa.This study examined how systemic inflammation, measured by inflammatory indices, interacts with the cardiometabolic index (CMI), a marker of obesity and dyslipidemia, to influence the risk of developing PCa.Methods: This study consisted of 1,591 male patients recruited from the Department of Urology at the First Affiliated Hospital of Xinjiang Medical University between 2022 and 2024. Propensity score matching was employed to adjust the sample size, resulting in a final cohort of 149 PCa patients and 296 matched controls. Logistic regression models and restricted cubic spline (RCS) analyses were employed to evaluate the associations between CMI and various inflammatory indices (e.g., PIV, SIRI, PLR, NLR, LMR) with prostate cancer. Interaction tests were conducted to investigate the impact of the interplay between inflammatory indices and CMI on the risk of prostate cancer.Results: NLR, PLR, PIV, and SIRI were significantly positively associated with prostate cancer (PCa) risk, whereas LMR exhibited a significant negative association. The CMI was significantly associated with an elevated risk of prostate cancer (PCa) (OR = 1.97, 95% CI: 1.38~2.81). Restricted cubic spline (RCS) analysis revealed a nonlinear dose-response relationship between CMI and prostate cancer (PCa) risk, with the risk plateauing at CMI ≈ 0.65. Sensitivity analyses confirmed the robustness of these results. Significant interactions were observed between CMI and inflammatory indices, particularly NLR, PLR, and LMR, suggesting synergistic effects on prostate cancer (PCa) risk.Conclusions: The present study demonstrated that inflammation indicators and CMI exhibited a strong association with the risk of PCa. Furthermore, a significant interaction was observed between CMI and inflammation indicators. These findings provide a novel perspective for PCa risk prediction and prevention, suggesting that inflammation and metabolic status should be considered together when assessing PCa risk.
Keywords: prostate cancer, Cardiometabolic index, Inflammation, neutrophillymphocyte ratio, Platelet lymphocyte ratio, systemic inflammation response index, Lymphocyte monocyte ratio
Received: 11 Mar 2025; Accepted: 23 Jun 2025.
Copyright: © 2025 Xiao, Tang, Wang, Cai, An and Tao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yunyun Xiao, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang Uyghur Region, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.